Business Wire
-
Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-407 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
3/21/2024
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.
-
IPA Acquires The Carterra LSA Instrument To Enhance Antibody Discovery And Bolster Its AI Developments
3/20/2024
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the LSA instrument platform from Carterra, a leading provider of high-throughput large and small molecule screening and characterization solutions.
-
Semarion Introduces SemaCyte Multiplexing Platform To Enhance Cell Assay Data Quality And Speed During Drug Discovery
3/20/2024
Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today introduced its SemaCyte Multiplexing Platform, an expansion to the existing SemaCyte Microcarrier platform to utilize optical barcoding to accelerate screening processes during in vitro drug discovery.
-
Takeda Announces U.S. FDA Approval Of Supplemental New Drug Application (sNDA) For ICLUSIG (Ponatinib) In Adult Patients With Newly Diagnosed Ph+ ALL
3/19/2024
Takeda today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
-
DNAnexus Adds NVIDIA NIM And CUDA-X Microservices To Precision Health Data Cloud To Accelerate Drug Discovery And Improve Patient Care
3/19/2024
DNAnexus, Inc., the provider of the Precision Health Data Cloud, today announced that it is integrating new NVIDIA NIM and CUDA-X microservices.
-
U.S. Food And Drug Administration (FDA) Has Accepted The New Drug Application (NDA) For Ensartinib
3/13/2024
Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ensartinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor for the treatment of adult patients with metastatic ALK-positive non-small cell lung cancer (NSCLC).
-
AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
3/11/2024
AbCellera and Biogen Inc. have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
-
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
3/11/2024
Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna).
-
Verastem Oncology Receives Orphan Drug Designation From FDA For Avutometinib Alone Or In Combination With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer
3/5/2024
Verastem Oncology a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to avutometinib, a RAF/MEK clamp, alone or in combination with defactinib, a selective FAK inhibitor, for the treatment of all patients with recurrent low-grade serous ovarian cancer (LGSOC).
-
bit.bio Announces First Project Within Multi-Year Collaboration Agreement With The Michael J. Fox Foundation (MJFF) To Generate Human Cell Products For Research And Drug Discovery In Parkinson’s Disease
3/5/2024
bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease (PD).